zedie posted: " Abstract BACKGROUND Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS In this phase 3, 12-month, do" Read on blog or Reader SOMEONE SOMEWHERE Read on blog or Reader A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis zedie February 29 Abstract BACKGROUND Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS In this phase 3, 12-month, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients who had had an inadequate response to or who had a history of unacceptable side effects with […] Read more of this post Comment Like You can also reply to this email to leave a comment.

SOMEONE SOMEWHERE © 2024. Manage your email settings or unsubscribe. Get the Jetpack app Subscribe, bookmark, and get real-time notifications - all from one app! Automattic, Inc. - 60 29th St. #343, San Francisco, CA 94110